Welcome to our dedicated page for Centogene N.V. Common Shares news (Ticker: CNTG), a resource for investors and traders seeking the latest updates and insights on Centogene N.V. Common Shares stock.
This page provides an archive of news and press releases related to Centogene N.V. (historically associated with the symbol CNTG). The company has described itself as the essential life science partner for data-driven answers in rare and neurodegenerative diseases, integrating multiomic technologies with the CENTOGENE Biodatabank to support diagnosis and pharmaceutical research.
News items for Centogene cover several themes. These include announcements about large-scale research initiatives such as the Rostock International Parkinson's Disease (ROPAD) Study, which focuses on the genetics of Parkinson’s disease and has generated findings on genetic risk factors and the prevalence of specific variants. Releases also describe collaborations in lysosomal diseases and Gaucher disease, including work with partners like Critical Path Institute and Evotec SE, where CENTOGENE’s data and biomarkers have been used alongside external platforms to identify and characterize potential therapeutic candidates.
Other historical news highlights corporate and financial developments, such as strategic collaborations, joint ventures, financing arrangements, and the company’s strategic alternatives review. A key set of announcements in late 2024 and early 2025 detail the agreement and subsequent closing of the sale of Centogene N.V.’s operating subsidiaries to an affiliate of Charme Capital Partners, shareholder approvals at an Extraordinary General Meeting, and the company’s stated intention to enter dissolution and liquidation following the transaction.
Because Centogene N.V. has reported that, after the sale of its operating subsidiaries, it and its remaining subsidiary will no longer have operations and will enter dissolution and liquidation, the CNTG news flow is best understood as a historical record. Investors and researchers can use this page to review how the company described its multiomic diagnostics, Biodatabank, research collaborations, and the sequence of corporate events leading up to the sale of its operating subsidiaries and planned liquidation.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.